Projects
Search from 1164 projects:
1164 Project(s)
IgPro20_3007: RECLAIM
Feb 5, 2020A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM)
Clinical Studies - Feb 5, 2020 - Dec 30, 2025
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Hutz Carina Liane, Bartz-Batliner Mira, Peischl Riana, Sasselli Clelia
PACIFIC AF
Jan 21, 2020Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to apixaban in patients with atrial fibrillation Primary Safet...
Clinical Studies - Jan 21, 2020 - Dec 7, 2021
Completed
Project leader: Rickli Hans
Members: Fink Karin, Vetsch Susanne
KSSG Collaborative Brain Tumour Registry
Jan 16, 2020Primary brain tumours remain an important burden of disease in Switzerland. Between 2010 – 2014, there were 1570 incident cases and about 580 deaths attributed to brain tumours each year. Although tumours of the central nervous system (CNS) represent...
Clinical Studies - Jan 16, 2020 - Jan 16, 2025
Ongoing
Project leader: Zeitlberger Anna, Hundsberger Thomas
Geringfügig induzierte Wehen bei einem geplanten Kaiserschnitt sollen das Befinden beim Neugeborenen und der Mutter verbessern – eine randomisierte Studie
Jan 1, 2020
Clinical Studies - Jan 1, 2020 - Dec 31, 2021
Automatically Closed
Project leader: Burkhardt T
Members: Fischer Tina
Metabolism of antiretroviral drugs in HIV infected patients with toxicity – a pilot study
Jan 1, 2020Antiretroviral drugs can be responsible for a wide range of toxic side effects ranging from acute events to long-term toxicity. We hypothesize that the microbiome-mediated metabolism plays a substantial role in antiretroviral drug toxicity through se...
Clinical Studies - Jan 1, 2020 - Dec 31, 2020
Automatically Closed
Project leader: Notter Julia, Zimmermann Michael, Kahlert Christian
Checkmate 73L (CA20973L)
Jan 1, 2020A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally A...
Clinical Studies - Jan 1, 2020 - Dec 11, 2023
Automatically Closed
Members: Glatzer Markus
Evaluation of the route of delivery after cesarean birth
Jan 1, 2020Diese single-center, retrospektive Studie beschäftigt sich mit der Entbindungsmethode von Frauen mit Status nach Sectio caesarea. Mit Hilfe der geburtshilflichen Datenbank Peridata analysieren wir die Entbindungsmethode (vaginale Entbindung vs. Re-Se...
Clinical Studies - Jan 1, 2020 - Dec 14, 2020
Automatically Closed
Project leader: Winder Franziska
Members: Tschenett Romina, Fischer Tina
Patienten Charakteristika und Outcome in Frauen mit klinischer Diagnose einer intrauterinen Infektion oder Inflammation oder beides (Triple I)
Jan 1, 2020Diese single-center, retrospektive Studie beschäftigt sich mit der Definition und klinischen Umsetzung von Triple I (intrauterine Infektion oder Inflammation oder beides) im Kantonsspital St. Gallen. Mit Hilfe der geburtshilflichen Datenbank Peridata...
Clinical Studies - Jan 1, 2020 - Dec 31, 2020
Automatically Closed
Project leader: Winder Franziska
Members: Becker Claudia, Fischer Tina
COVI-PREG - Internationales Register von Patientin, für die eine SARS-CoV-2 Infektion während der Schwangerschaft vermutet wird
Jan 1, 2020
Fundamental Research - Jan 1, 2020 - Dec 31, 2021
Automatically Closed
Project leader: Baud David
Members: Panchaud Alice, Fischer Tina
Potential treatment approach for severe preeclampsia by using nanoparticles
Jan 1, 2020Preeclampsia is a severe pregnancy associated disease. An antiangiogenic environment is created by an excessive production of sFlt-1. The only current therapeutic option is delivery of the child and placenta. First experimental evidence for the thera...
Fundamental Research - Jan 1, 2020 - Dec 31, 2021
Automatically Closed
Project leader: Herrmann Inge
Members: Rduch Thomas, Fischer Tina, Hornung René
Predictive markers for checkpoint-based immunotherapy in advanced non-small cell lung cancer
Jan 1, 2020The aim of this study is to elucidate a novel biomarker constellation with superior predictive value for PD-1/PD-L1-targeted immunotherapy in advanced non-small cell lung cancer.
Fundamental Research - Jan 1, 2020 - Dec 31, 2021
Completed
Project leader: Bösch Maximilian
Members: Baty Florent, Brutsche Martin, Früh Martin, Jörger Markus
Nanopartikel und Fremdstoffe an der menschlichen Plazenta: Transport, Aufnahme und biologische Effekte
Jan 1, 2020Ziel dieser Untersuchungen ist es herauszufinden, wie sich Fremdstoffe oder Nanomaterialien, inklusive endogene Kalkpartikel, an der Plazentaschranke verhalten, z. B. wie rasch und in welcher Konzentration sie vom mütterlichen in das kindliche Blut g...
Fundamental Research - Jan 1, 2020 - Dec 31, 2021
Automatically Closed
Project leader: Bürki Tina, Fischer Tina
Members: Aengenheister Leonie, Dugershaw Battuja, Chortarea Savvina, Hannig Yvette, Rduch Thomas, Herrmann Inge, Hornung René
EMCL-Registry of the European Mantle Cell Lymphoma study group
Dec 20, 2019Klinisches Register des „Europäischen Mantelzelllymphom Netzwerk (EMCL)“. Erfassung von Patienten mit neu diag-nostiziertem oder rezidiviertem Mantelzelllymphom
Clinical Studies - Dec 20, 2019 - Dec 20, 2025
Ongoing
Project leader: Fehr Martin
EMCL-Registry of the European Mantle Cell Lymphoma study group
Dec 20, 2019
Clinical Studies - Dec 20, 2019 - Dec 31, 2030
Ongoing
Project leader: Fehr Martin
Members: Steiner Marianne
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenancetherapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Dec 18, 2019IDH1 or IDH2 mutations are each found in about 10% of AML – and specific inhibitors are approved or in development in this indication. The primary objective of this study is to compare event-free survival (EFS) between ivosidenib/enasidenib and pl...
Clinical Studies - Dec 18, 2019 - Jan 31, 2027
Ongoing
Project leader: Schittenhelm Marcus
Members: Kehl Jeanine, Quinter Janine
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL,
Dec 15, 2019Palliative systemic treatment option in Her2 low patients after one, max. 2 chemotherapy lines
Clinical Studies - Dec 15, 2019 - Dec 10, 2022
Automatically Closed
SMArtCare: Longitudinal data assessment from patients with spinal muscular atrophy
Dec 9, 2019Erfassung klinischer Barameter bei Patienten mit SPinaler Muskelatrophie mit und ohne krankheitsmodifizeirende Therapie. Registerstudie.
Clinical Studies - Dec 9, 2019 - Dec 31, 2030
Ongoing
Project leader: Neuwirth Christoph
A Phase 1b/2 Multicenter, Open-label, Expansion Study to As-sess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
Dec 5, 2019Bispezifische, T-Zell-aktivierende Antikörper (BITE) sind eine vielversprechende Option, um eine zellvermittelte Immuntherapie von Tumoren zu erreichen. In der vorlie-genden Studie wird die Wirksamkeit und Sicherheit eines gegen das Oberflächenantige...
Clinical Studies - Dec 5, 2019 - Dec 23, 2020
Automatically Closed
Project leader: Driessen Christoph
Members: Silzle Tobias
Six-Minute Walking Test (6WT) as a measure of objective functional impairment in lumbar spinal stenosis. Validation and realtionship to subjective measure of pain, function and quality of life
Dec 1, 2019Background: Lumbar spinal stenosis (LSS) is a progressive, degenerative disorder of the aging spine presenting with lower back pain, which commonly progresses into neurogenic claudication which impedes walking. The precise measurement of symptom seve...
Clinical Studies - Dec 1, 2019 - May 1, 2022
Automatically Closed
Project leader: Maldaner Nicolai
XATOA – Xarelto + Acetylsalicylic Acid: Treatment
Nov 19, 2019The study aims to collect real-world data on treatment patterns and decision points for treatment in patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) treated with rivaroxaban 2.5 mg[BID] for the prevention of...
Clinical Studies - Nov 19, 2019 - Dec 21, 2021
Completed
Project leader: Rickli Hans
Members: Fink Karin